Refine by
Pharmaceutical Clinical Articles & Analysis
117 news found
This achievement highlights Huateng Pharma’s dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting the pharmaceutical industry’s research and clinical needs. The successful DMF filing demonstrates that Huateng Pharma’s production processes and quality control systems fully comply with FDA ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
The company offers a variety of products and services for businesses of all sizes, including data analysis, modeling, and strategy consulting, with a broad client base in industries such as pharmaceutical and clinical, finance, and ...
Efficient leadership plays a huge role in bringing a clinical trial to fruition. Pharmaceutical companies are not immune to making mistakes and facing failures. ...
By eliminating the need for additional immunohistochemistry, 4D Path’s cloud-based platform accelerates complete, actionable and objective insight leading to expedited and democratized precision medicine for optimized patient care and clinical trials. 4D Path’s cloud-based, quantitative approach provides clinical solutions in both companion ...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. ...
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform ...
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ...
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement. ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. ...
To view LIXTE Biotechnology Holdings' presentation at the Planet MicroCap conference, register in advance at: https://planetmicrocapshowcase.com/signup The Planet MicroCap Showcase: VIRTUAL 2022 website is available at https://planetmicrocapshowcase.com/ All company presentations as part of the conference will be available directly on the conference event platform on this link under the tab ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will ...
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual ...
Drug formulation, or pharmaceutical formulation, is a universal challenge faced by biotech companies developing new drugs that enter clinical trials. ...
Today, DNAnexus has more than 12,000 users across 48 countries and works with the largest and most innovative pharmaceutical companies, diagnostic laboratories, and academic medical centers around the world, along with the UK Biobank and the FDA. ...
Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology. ...
This clearance further validates the quality and clinical efficacy of the company’s artificial intelligence (AI)-powered precision imaging and analytics solutions. ...
(Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has authorized a Phase 1b/randomized Phase 2 study of ...
Pravibismane has also demonstrated safety in multiple clinical studies including treatment of patients with diabetic foot infections and patients with serious orthopedic device-related infections. Several positive signals of efficacy (not statistically significant) were appreciated in these early clinical studies. About Microbion Microbion is a ...